10 results about "Terbinafine" patented technology

The invention relates to otological formulations, methods and devices. The present invention relates to a formulation and a method for treating ear infections, in particular auricular mycosis and otitis externa, by single administration. The formulations comprise an antibiotic, an antifungal agent and an anti-inflammatory agent added to a thick ear carrier. In one embodiment, the formulation comprises a therapeutically effective amount of an active ingredient, including marbofloxacin, terbinafine and / or clotrimazole and dexamethasone.

The invention discloses an application of celecoxib or a pharmaceutical salt thereof in preparation of an antifungal drug synergist. An antifungal drug is selected from an azole antifungal drug, an allylamine antifungal drug or an echinocandin antifungal drug. The azole antifungal drug is selected from the group consisting of fluconazole, voriconazole, itraconazole, posaconazole and isavuconazole; the allylamine antifungal drug is selected from terbinafine; the echinocandin antifungal drug is selected from caspofungin. In-vivo and in-vitro experiments prove that when the celecoxib is combined with the azole antifungal drug and the allylamine antifungal drug terbinafine, a synergistic antifungal effect is shown, and when the celecoxib is combined with the echinocandin antifungal drug caspofungin, an additive effect is shown. Celecoxib and fluconazole are combined for use, so that the survival rate of fungal infected animals can be increased, and toxicity to wax moth larvae and mammalian cells is low.

The invention discloses an application method for controlling cotton verticillium wilt by utilizing terbinafine to target verticillium dahliae sterol binding protein VdPBP1, and relates to the technical field of cotton control, and the method comprises the following application steps: S1, confirming the characteristics of a terbinafine medicament; s2, formulating a terbinafine application scheme; and S3, verification and guarantee of prevention and control effects. According to the method, theoretical support is provided for precise prevention and control; the EC50 of the terbinafine is 10.8 ng / mL, the dosage of the medicament can be greatly reduced, the monovalence of the terbinafine is 30.4 yuan / g, so that the large-scale application cost is lower, the terbinafine is only combined with verticillium dahliae VdPBP1 and blocks mediated electron transfer of the verticillium dahliae VdPBP1, and the existing medicaments such as phenazino-1-carboxylic acid can inhibit histone acetylation and benomyl has wide action targets of interfering microtubulin, so that the application range of the medicament is widened. Non-target organisms are easily influenced; moreover, an ergosterol synthesis pathway is an essential pathway for fungi, and the VdERG1 is a single copy gene in verticillium dahliae, so that pathogenic bacteria are difficult to generate drug resistance through gene mutation, and prevention and control nodes widely cover the whole growth period.

This invention relates to a composition of ellagic acid and terbinafine and its application in the preparation of drugs for treating bladder cancer, belonging to the field of biomedical technology. To address the problem that terbinafine treatment of bladder cancer easily causes compensatory increases in SQLE expression levels, this invention provides a composition of ellagic acid and terbinafine, consisting of ellagic acid and terbinafine in a mass ratio of 5:8. This invention uses this composition in the preparation of drugs for treating bladder cancer. Terbinafine can directly inhibit SQLE enzyme activity, blocking cholesterol synthesis and inhibiting tumor growth, while ellagic acid can reduce the compensatory upregulation of SQLE expression caused by terbinafine alone. The synergistic effect of the two can reduce the metabolic side effects caused by terbinafine and the drug toxicity of ellagic acid, significantly enhancing the anti-bladder cancer effect and overcoming monotherapy resistance. This invention is based on the development of already marketed drugs, possessing the dual advantages of therapeutic enhancement and improved safety, providing a more optimized treatment plan for bladder cancer.

The invention relates to an ellagic acid and terbinafine composition and application thereof to preparation of a medicine for treating lung cancer, and belongs to the technical field of biological medicine. In order to solve the problem that in the prior art, when a single drug of terbinafine is used for treating lung cancer, SQLE feedback is increased, the invention provides an ellagic acid and terbinafine composition which is composed of ellagic acid and terbinafine in a mass ratio of 4: 7. The pharmaceutical composition provided by the invention is used for preparing a medicine for treating lung cancer, and the composition can inhibit SQLE in a targeted manner through dual mechanisms, block a cholesterol biosynthesis pathway and inhibit tumor growth; through the synergistic effect of the terbinafine and the ellagic acid, the anti-tumor effect is remarkably improved, adverse reactions such as metabolic disorder caused by the terbinafine can be reduced, the drug toxicity of the ellagic acid is reduced, and the drug resistance is effectively prevented. The pharmaceutical composition is developed on the basis of commercially available drugs, has the dual advantages of enhancing the curative effect and improving the safety, and provides a more optimized treatment scheme for lung cancer treatment.

This invention relates to a composition of ellagic acid and terbinafine and its application in the preparation of drugs for treating lung cancer, belonging to the field of biomedical technology. To address the problem of increased SQLE feedback during terbinafine monotherapy for lung cancer in existing technologies, this invention provides a composition of ellagic acid and terbinafine, consisting of ellagic acid and terbinafine in a mass ratio of 4:7. The pharmaceutical composition provided by this invention is used to prepare drugs for treating lung cancer. This composition can target and inhibit SQLE through a dual mechanism, blocking cholesterol biosynthesis pathways and inhibiting tumor growth; the synergistic effect of the two significantly enhances the anti-tumor effect, while also reducing adverse reactions such as metabolic disorders caused by terbinafine, mitigating the drug toxicity of ellagic acid itself, and effectively preventing the development of drug resistance. This invention is based on the development of already marketed drugs, possessing the dual advantages of enhanced efficacy and improved safety, providing a more optimized treatment plan for lung cancer.

The present invention relates to a formulation and method for treating an ear infection, especially otomycosis and otitis externa, by administering a one-time only treatment comprising an antibiotic, antifungal, and an anti-inflammatory in a thick, otic carrier. In one embodiment, the formulation comprises a therapeutically effective amount of active ingredients including a marbofloxacin, terbinafine and / or clotrimazole and dexamethasone.

The present invention relates to a composition for use in the treatment of a fungal infection comprising a polymer capable of forming nanoparticles and terbinafine, or derivative or salt thereof, wherein the nanoparticles are formed with and / or in the presence of terbinafine, or derivative or salt thereof, and where the composition comprises: a) a ratio of terbinafine, or derivative or salt thereof, to polymer in the range of about 1:2 to 1:4; and b) up to about 30% (v / v) alcohol. The composition is particularly suited as a topical treatment for fungal nail or skin infections. The invention also relates to methods of producing such compositions and combinations which can be used to produce said same.

The invention relates to an ellagic acid and terbinafine composition and application thereof to preparation of a medicine for treating bladder cancer, and belongs to the technical field of biological medicine. The invention provides an ellagic acid and terbinafine composition which is used for solving the problem that the compensation of SQLE expression level is easily increased when terbinafine is used for treating bladder cancer, and the ellagic acid and terbinafine composition is prepared from ellagic acid and terbinafine in a mass ratio of 5: 8. The application is used for preparing the bladder cancer treatment medicine, terbinafine can directly inhibit SQLE enzyme activity, block cholesterol synthesis and inhibit tumor growth, ellagic acid can reduce SQLE expression compensatory up-regulation caused by independent treatment of terbinafine, metabolic side effects caused by terbinafine and medicine toxicity of ellagic acid can be reduced through synergism of terbinafine and ellagic acid, and the bladder cancer treatment medicine can be used for treating bladder cancer. The bladder cancer resisting effect is obviously enhanced, and the single drug resistance is overcome. Based on the development of medicines on the market, the traditional Chinese medicine composition has the double advantages of treatment synergy and safety improvement, and a more optimized treatment scheme is provided for bladder cancer treatment.

The present invention relates to a formulation and method for treating an ear infection, especially otomycosis and otitis externa, by administering a one-time only treatment comprising an antibiotic, antifungal, and an anti-inflammatory in a thick, otic carrier. In one embodiment, the formulation comprises a therapeutically effective amount of active ingredients including a marbofloxacin, terbinafine and / or clotrimazole and dexamethasone.